Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial
Author:
- 15 February 2008
- journal article
- research article
- Published by Journal of Chinese Integrative Medicine Press in Journal of Chinese Integrative Medicine
- Vol. 6 (2) , 134-138
Abstract
To our knowledge, there has been no clinical report of artesunate in the treatment of lung cancer. This study was designed to compare the efficacy and toxicity of artesunate combined with NP (a chemotherapy regimen of vinorelbine and cisplatin) and NP alone in the treatment of advanced non-small cell lung cancer (NSCLC). One hundred and twenty cases of advanced NSCLC were randomly divided into simple chemotherapy group (control group, n=60) and combined artesunare with chemotherapy group (trial group, n=60). Patients in the control group were treated with NP regimen, including vinorelbine (25 mg/m(2), once-a-day intravenous injection, at the 1st and 8th day) and cisplatin (25 mg/m(2), once-a day intravenous drip, at the 2nd to 4th day). Patients in the trial group were treated with the basal therapy NP (in the same method and doses as control group) and artesunate (120 mg, once-a-day intravenous injection, from the 1st day to 8th day, for 8 days). At least two 21-day-cycles of treatment were performed. The short-term survival rate, disease controlled rate (DCR), time to progression (TTP), mean survival time (MST) and 1-year survival rate were analyzed as the primary end points, and the toxicity and safety were estimated. There were no significant differences in the short-term survival rate, MST and 1-year survival rate between the trial group and the control group, which were 45.1% and 34.5%, 44 weeks and 45 weeks, 45.1% and 32.7%, respectively (P>0.05). The DCR of the trial group (88.2%) was significantly higher than that of the control group (72.7%) (P0.05). Artesunate can be used in the treatment of NSCLC. Artesunate combined with NP can elevate the short-term survival rate and prolong the TTP of patients with advanced NSCLC without extra side effects.Keywords
This publication has 8 references indexed in Scilit:
- Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous ironFree Radical Biology and Medicine, 2004
- Molecular Modes of Action of Artesunate in Tumor Cell LinesMolecular Pharmacology, 2003
- Overall Survival Is Not a Realistic End Point for Clinical Trials of New Drugs in Advanced Solid Tumors: A Critical Assessment Based on Recently Reported Phase III Trials in Colorectal and Breast CancerJournal of Clinical Oncology, 2003
- Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cellsCancer Letters, 2002
- Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cellsLife Sciences, 2001
- Artemisinin and its derivatives: an important new class of antimalarial agentsPharmacology & Therapeutics, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Reporting results of cancer treatmentCancer, 1981